



Brian Dovey Elected Chairman

San Diego, California (Tuesday, March 29, 2016, PDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce that its board of directors has elected Brian Dovey to be Chairman. Mr. Dovey has been a member of REVA’s board for almost 15 years and has served on its compensation and audit committees. Mr. Dovey will replace Robert Stockman, the Company’s current Chairman, who will remain on the board as a non-executive director.

Mr. Dovey is a partner of Domain Associates, LLC, a leading venture capital firm focused on life sciences. He joined REVA’s board in 2001 when Domain first invested in the Company. Mr. Dovey has served on the boards of over 35 private and public companies and has been Chairman of five. Prior to Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now part of Sanofi-Aventis), a pharmaceutical and medical device company listed on the NYSE. As President of Rorer, he was the primary architect of the company’s strategic shift to pharmaceuticals. Previously, he was President of Survival Technology, Inc., a publicly-traded medical products company. Mr. Dovey received his B.A. in mathematics from Colgate University and his MBA from the Harvard Business School.

Commenting on the transition, Mr. Stockman said, “I am very pleased to turn the reins over to someone with Brian’s experience and stature. I am confident he will continue to move the Company down the path we set to become a world-class, innovative cardiology company.”

Mr. Dovey’s appointment is effective immediately.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds.” The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the *Fantom*[®] scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize *Fantom* or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States**Investor & Media Enquiries:**

REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia**Investor Enquiries:**

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia**Media Enquiries:**

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722